9 November 2022: Expert Group on Statistics - B

The second interquartile session of statistics expert group evidence returned to HCV infections of bleeding disorder patients. The number were influenced by developing medical interventions, for example, the survival rates of HIV co-infected people improved due to better treatments, whereas the original anti-viral treatments for HCV alone were not well tolerated and not very effective (the Interferon-based treatments). It was highlighted that HCV does not just affect the liver, but also the brain, the heart, and the kidneys, for example.

Counsel sought to drill-down on mortality rates, but there were difficulties with generalisations that go beyond liver-related factors. It was agreed that there will likely be a number of other “unknown” deaths arising from HCV but it has not been possible to record these.

At one point the word “guess” was replaced with “judgemental estimate” which created some polite light relief from the numerical numbness. This euphemistic reframing had been connected to an almost impenetrable section of presentation over number sets and their meaning. Penrose got a mention in relation to numbers of deaths “from AIDS” which suggested an overall higher risk within the Scottish population, possibly due to higher rates of needle use. That could reflect a higher HIV prevalence in the donor population, too. The Eileen Trust (set up for non-bleeding disorder HIV infectees) noted how it was difficult to always record the country of transfusion infection.

Counsel shifted to the shorter sections of the report covering vCJD and HBV. There were five confidently known cased of vCJD connected to blood infection routes (four transfusion-related, one from bleeding disorder product use). The triangulation method was used to strengthen the conclusions since there was not a test or procedure for determining vCJD infection other than post-mortem. More generally, the majority of vCJD infectees died within 5 years of being infected, but there was no post-mortem carried out on these earlier patients, so it was not possible to know if vCJD was the actual cause of death.

The question was posed about any on-going risk of vCJD to those who had been advised of possible exposure to an implicated batch of blood or blood product. The panel responded that it simply was not possible to say what the risk might be, if any.

On HBV, the major difficulty was the lack of data. Because there had been no financial support provision which would have required peoples’ information be gathered, it was not possible for the panel to draw any conclusions since these would be very unreliable. The data on HBV infection is just not there, even to allow modelling methods to be applied.

Comments

Popular posts from this blog

26 July 2023: Sunak - A

25 July 2023: Dunn - B

17 November 2022: Panel on finding the undiagnosed - A